Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy

Abstract

Aims/hypothesis. Poly(ADP-ribose) polymerase activation depletes NAD + and high-energy phosphates, activates protein kinase C, and affects gene expression in various tissues. This study was designed to characterise the effects of the potent, orally active poly(ADP-ribose) polymerase inhibitor PJ34 in the Wistar rat model of early diabetic neuropathy. Methods. Control and streptozotocin-diabetic rats were maintained with or without PJ34 treatment (30 mg·kg −1 ·day −1 ) for two weeks, after two weeks without treatment. Endoneurial blood flow was assessed by hydrogen clearance; metabolites and highenergy phosphates were assayed by enzymatic spectrofluorometric methods; and poly(ADP-ribose) was detected by immunohistochemistry.Results. Blood glucose concentrations were increased to a similar extent in untreated and PJ34-treated diabetic rats compared with controls. Intense poly(ADPribose) immunostaining was observed in the sciatic nerve of diabetic rats, but not in other groups. Final sciatic motor nerve conduction velocity and digital sensory nerve conduction velocity were reduced by 24% and 22% respectively in diabetic rats compared with controls (p<0.01 for both), and both were 98% corrected by PJ34 (p<0.01 vs diabetic group for both).In contrast, with PJ34 treatment, nerve blood flow showed a modest (17%) increase, and vascular conductance showed a tendency to increase. Free mitochondrial and cytosolic NAD + :NADH ratios, assessed from the glutamate and lactate dehydrogenase systems, phosphocreatine concentrations, and phosphocreatine:creatine ratios were decreased in diabetic rats and essentially normalised by PJ34. In both untreated and PJ34-treated diabetic rats, nerve glucose, sorbitol and fructose were increased to a similar extent. PJ34 did not affect any variables in control rats. Conclusions/interpretation. Short-term poly(ADP-ribose) polymerase inhibitor treatment reverses functional and metabolic abnormalities of early diabetic neuropathy. Complete normalisation of nerve blood flow is not required for correction of motor or sensory nerve conduction velocities, provided that a therapeutic agent can restore nerve energy state via direct action on Schwann cells.Keywords Energy state · Motor and sensory nerve conduction · Nerve blood flow · Oxidative and nitrosative stress · Peripheral diabetic neuropathy · PJ34 · Poly(ADP-ribose) polymerase · Rat · Sorbitol pathway of glucose metabolism · Streptozotocindiabetes

Mitochondrial Respiratory Chain Dysfunction in Dorsal Root Ganglia of Streptozotocin-Induced Diabetic Rats and Its Correction by Insulin Treatment

“…In diabetic rats, activity of 6-phosphofructokinase is reduced in nerve (35), and activity of hexokinase, the first rate-limiting step in glycolysis, is reduced in DRG (36). Diminished activity of glycolytic pathway enzymes may combine to reduce delivery of pyruvate and other glucose metabolism-dependent products to the tricarboxylic acid pathway (32–34,37), and it has been shown that pool sizes of products of glycolysis, such as pyruvate, are either unchanged or reduced in diabetes (33,38). It therefore appears that rates of electron donation to the electron transport chain are suboptimal in adult diabetic rats and may predispose to lower rates of mitochondrial respiratory chain activity and oxidative phosphorylation.…”

Insulin in Central Nervous System: More than Just a Peripheral Hormone

“…Importantly, NF- κ B activation has been shown to increase Cu/Zn -superoxide dismutase (SOD) expression and MnSOD levels after H 2 O 2 and amyloid beta (A β ) treatment, protecting against oxidative stress and apoptosis in PC12 and NT2 cells, respectively [77, 78]. Alternatively, PI-3K/Akt activation may promote neuronal and glial antioxidant defences by stimulation of the Nrf-2/antioxidant responsive element (ARE) [79]. …”

Nutrient excess and altered mitochondrial proteome and function contribute to neurodegeneration in diabetes

“…SIRT1-mediated regulation of PGC-1α activity may play a major role in the metabolic adaptations to energy metabolism in different tissues (Canto and Auwerx, 2010). Recent work shows high glucose can down-regulate SIRT1 expression in endothelial cells (Balestrieri et al, 2008) and the diabetic state lowers the NAD + /NADH ratio in retina and nerve (Ido et al, 2010; Li et al, 2004; Oates, 2008; Obrosova et al, 2006). …”